Loading
Rilvegostomig is an experimental bispecific antibody from AstraZeneca in phase 2 trials for non-small-cell lung cancer, aimed at PD-1 and TIGIT.
Rilvegostomig (AZD2936) is a bispecific antibody developed by AstraZeneca. Its targets are PD-1 and TIGIT (the sponsor names TIGIT x PD-1). The sponsor states: Rilvegostomig (AZD2936) is an anti-TIGIT/anti-PD-1 bispecific antibody given intravenously as monotherapy to enhance anti-tumour immune response in advanced/metastatic NSCLC with PD-L1 expression. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT04995523, plans to enrol 212 participants (actual) with primary completion was scheduled for 2026-08-28 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.One arm of Rilvegostomig binds PD-1 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Rilvegostomig" OR ABSTRACT:"Rilvegostomig" OR TITLE:"AZD2936" OR ABSTRACT:"AZD2936") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Rilvegostomig, not a curated reading list.
Shares A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares PD-1, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares TIGIT, Non-small-cell lung cancer and the tag pipeline.
Shares Compugen and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.